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Potential effect of household contact management on 
childhood tuberculosis: a mathematical modelling study
Peter J Dodd, Courtney M Yuen, Mercedes C Becerra, Paul Revill, Helen E Jenkins, James A Seddon
Summary
Background Tuberculosis is recognised as a major cause of morbidity and mortality in children, with most cases in 
children going undiagnosed and resulting in poor outcomes. Household contact management, which aims to identify 
children with active tuberculosis and to provide preventive therapy for those with HIV or those younger than 5 years, 
has long been recommended but has very poor coverage globally. New guidelines include widespread provision of 
preventive therapy to children with a positive tuberculin skin test (TST) who are older than 5 years.
Methods In this mathematical modelling study, we provide the irst global and national estimates of the impact of 
moving from zero to full coverage of household contact management (with and without preventive therapy for 
TST-positive children older than 5 years). We assembled data on tuberculosis notiications, household structure, 
household contact co-prevalence of tuberculosis disease and infection, the eicacy of preventive therapy, and the 
natural history of childhood tuberculosis. We used a model to estimate households visited, children screened, and 
treatment courses given for active and latent tuberculosis. We calculated the numbers of tuberculosis cases, deaths, 
and life-years lost because of tuberculosis for each intervention scenario and country.
Findings We estimated that full implementation of household contact management would prevent 159 500 
(75% uncertainty interval [UI] 147 000–170 900) cases of tuberculosis and 108 400 (75% UI 98 800–116 700) deaths in 
children younger than 15 years (representing the loss of 7 305 000 [75% UI 6 663 000–7 874 000] life-years). We 
estimated that preventing one child death from tuberculosis would require visiting 48 households, screening 
77 children, giving 48 preventive therapy courses, and giving two tuberculosis treatments versus no household 
contact management.
Interpretation Household contact management could substantially reduce childhood disease and death caused by 
tuberculosis globally. Funding and research to optimise its implementation should be prioritised.
Funding UK Medical Research Council, US National Institutes of Health, Fulbright Commission, Janssen Global 
Public Health.
Copyright © 2018 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license.
Introduction
Tuberculosis is the leading infectious cause of mortality 
worldwide, afecting an estimated 1 million children in 
2016, of whom an estimated 253 000 died in 2016.1 
Tuberculosis is a top ten cause of global under-5 mortality,2 
with most deaths each year occurring among the roughly 
half a million children who are never diagnosed or 
treated.2,3 Younger children are more likely to develop 
severe forms of tuberculosis, such as tuberculous 
meningitis, that are often fatal or have long-term sequelae 
(eg, neurological deicits).4 These deaths and long-term 
efects have a substantial impact on families and society; 
these young children would otherwise have had many 
decades of productive life ahead of them. To reduce the 
burden of childhood tuberculosis disease and death, more 
children with tuberculosis need to be diagnosed and 
treated or prevented from becoming sick with tuberculosis 
in the irst place. Preventing cases of tuberculosis is 
especially important in resource-limited settings, where 
the diagnosis of children with tuberculosis can be 
particularly challenging.
One of the most efective ways of identifying children 
with both tuberculosis infection and disease is through 
household contact investigations, because children living 
in the homes of adults with tuberculosis are at high risk 
of both infection and disease.5 Systematically assessing 
child household contacts can ensure that children with 
tuberculosis disease are diagnosed and treated early, and 
that children with tuberculosis infection or exposure are 
given preventive therapy to prevent them from becoming 
sick in the future. Since 2012, WHO guidance has 
recommended household contact investigations for 
patients with tuberculosis and preventive therapy for 
children younger than 5 years and people living with 
HIV.6 In 2018, this guidance was updated to include the 
option of preventive therapy for older contacts with a 
positive tuberculin skin test (TST) in settings with a high 
tuberculosis burden.7 Despite the fact that many national 
policies incorporate these recommendations,8,9 major 
gaps exist in the implementation of household contact 
management (HCM).10,11 Worldwide, only 13% of eligible 
children younger than 5 years are estimated to receive 
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preventive therapy.1 Competing priorities, low 
awareness, infra structural challenges, stigma, and 
inadequate access to care are all barriers.10 Until recently, 
HCM activities were not routinely included in 
monitoring and reporting systems; coverage of 
preventive therapy to children younger than 5 years who 
are household contacts of bacteriologically conirmed 
pulmonary tuberculosis has now been requested and 
reported by WHO since 2016.1
Given the poor implementation of household contact 
investigations and preventive therapy despite universal 
acknowledgment of their importance, we aimed to 
quantify the potential efect that full use of these 
interventions could have. This knowledge would permit 
an analysis of the efect of HCM compared with other 
childhood tuberculosis measures or other measures to 
reduce child mortality. We brought together available data 
within a mathematical modelling frame work to estimate 
the potential global reduction in childhood tuberculosis 
disease and death that child-targeted household contact 
interventions could achieve if taken to scale.
Methods
Study design
We did a mathematical modelling study in the global 
population of children younger than 15 years cohabiting 
with a patient diagnosed with tuberculosis. We assessed 
the efect of full versus zero HCM coverage, estimating 
outcomes for demands on the health-care system and 
child morbidity and mortality. We used a two-stage process, 
developing regression-based estimates of numbers of child 
household contacts, and then combining these with a 
decision tree model to estimate their outcomes (igure 1).
Interventions and outcomes
We considered three scenarios: scenario A approximates 
the status quo in which HCM is not routinely done in 
high-burden settings.10,11 In scenario A, we assumed that 
co-prevalent and incident tuberculosis in children would 
be detected and treated with the country-speciic case 
detection rate for children cohabiting with patients 
diagnosed with tuberculosis. Scenario B relects the long-
standing WHO recommendations for the management 
of tuberculosis households in high-burden settings 
before 2018.6 In this scenario, we assumed that tuber-
culosis screening for all household contacts younger than 
15 years and preventive therapy for all children younger 
than 5 years and all HIV-positive children younger 
than 15 years were done. Scenario C extends scenario B 
to relect updated recommendations from 20187 by 
expanding the use of preventive therapy to TST-positive 
children aged 5–14 years. In scenarios B and C, we do not 
account for screening or preventive therapy for cohabiting 
adults, and assume that the case detection rate for 
incident childhood tuberculosis disease is unafected by 
screening activities. To assess maximal impact, we 
assumed complete intervention coverage, recognising 
that this is an idealised scenario. We based the yield of co-
prevalent tuberculosis in child household contacts on 
empirical data derived from household contact studies.5 
Research in context
Evidence before this study
We did a PubMed search in March, 2018, using the search terms 
“Tuberculosis” AND “Household” AND “Contact” AND “Child*” 
AND “Model*”. We found 65 articles, from which we identified 
two studies modelling the effect of household contact 
management of children. Morrison and colleagues and Fox and 
colleagues each conducted a systematic review and 
meta-analysis on the co-prevalence of tuberculosis disease and 
infection in household contacts and reported similar findings, 
which we used in our analysis. We used systematic reviews and 
meta-analyses on the efficacy of isoniazid preventive therapy in 
preventing tuberculosis in children who are HIV negative 
(Ayieko and colleagues) and HIV positive (Zunza and colleagues) 
in our analysis. Mandalakas and colleagues did a cost-
effectiveness analysis of household contact activities focused on 
children younger than 5 years using South African cost data and 
found it to be a cost-effective intervention, but did not consider 
co-prevalent cases. Our analysis focused on hypothetical cohorts 
of household contacts and did not assess the numbers of 
household contacts. Yuen and colleagues estimated the number 
of child contacts expected from household contact activities, 
but not the effect of such activities on tuberculosis disease and 
death in children.
Added value of this study
Our study is the first to project the effect on childhood disease 
and death of tuberculosis household contact management 
among children, by bringing together models of contact 
numbers and of cohort outcomes for 217 countries and 
territories. We incorporated systematic review evidence on 
yields of household contact investigations in children, 
child-specific efficacy of preventive therapy and tuberculosis 
outcomes, and data on HIV and antiretroviral therapy. We also 
include the benefits of identifying co-prevalent tuberculosis 
disease in children and of preventing incident disease.
Implications of all the available evidence
Household contact activities for tuberculosis could have 
potentially prevented the loss of about 110 000 lives with 
7 million years of life expectancy in 2016 in children younger 
than 15 years, with measures of  demands on the health-care 
system that suggest excellent value for money. The global use 
of household contact management should be increased. 
Operational research and local cost-effectiveness analysis to 
inform implementation should be priorities.
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In each of these studies, the diagnosis of childhood 
tuberculosis was made using the diagnostic tools that 
were available in their setting, with associated imperfect 
sensitivity and speciicity.
As measures of demands on the health-care system, we 
calculated the number of households, the number of 
cohabiting children who would be screened, the number 
who would be given anti-tuberculosis treatment for active 
disease (including those found through passive case 
detection), and the number who would receive preventive 
therapy.
As measures of morbidity and mortality, we calculated 
the numbers of children who had prevalent disease at 
the time of the index patient’s diagnosis (co-prevalent), 
who develop incident tuberculosis disease within 1 year 
(incident), and who die from tuberculosis within 1 year. 
Our estimates of risk of co-prevalent tuberculosis 
disease and mortality if treated or untreated were 
derived from empirical data,3,5 relecting the realities of 
diagnosing tuberculosis disease in children with 
imperfect sensitivity and speciicity. We also estimated 
the total years of expected life in cohabiting children to 
be able to establish years of expected life gained via 
intervention.
To describe the impact of each intervention scenario, 
we calculated diferences in outcomes of interest between 
scenarios A and B and between scenarios A and C. 
Additionally, we calculated the number of household 
visits, screened children, preventive therapy, and anti-
tuberculosis treatment courses per tuberculosis death 
averted and per case averted. We calculated each outcome 
for each country under each scenario. Uncertainty was 
modelled in all input parameters and summaries from 
1000 sampled parameter sets reported stratiied by age 
and region as well as globally.
Model for numbers of contacts
To predict the number of children younger than 5 years 
and those aged 5–14 years cohabiting with patients 
diagnosed with tuberculosis of a given age and sex, we 
developed a Bayesian multivariate regression model 
based on data from Demographic and Health Surveys 
from 69 countries with standardised comparable data on 
household composition. The response data were (simul-
taneously) the mean number of children in each of the 
two age groups living with men and women in the age 
groups of 15–24 years, 25–34 years, 35–44 years, 
45–54 years, 55–64 years, and 65 years and older. A 
sensitivity analysis for India based on a Demographic 
and Health Survey that included a question on self-
reported tuberculosis explored the potential for house-
holds of patients diagnosed with tuberculosis to 
systematically difer, controlling for index patient age 
and sex. Survey design was accounted for in calculating 
conidence intervals for contact numbers, and a 
measurement model included this sample uncertainty 
in the regression analysis. World Bank data on per capita 
gross domestic product, life expectancy at birth, infant 
mortality, population fraction younger than 15 years, 
population fraction living in urban areas, population 
density, and total fertility were used as country-level 
predictors. We ran this model on the most recent World 
Bank data to predict the number of child household 
contacts in each country and age group for each of 
180 countries, and combined this with WHO age-
stratiied and sex-stratiied tuberculosis notiication data 
Tuberculosis 
notifications by 
age and sex (WHO)
Model of 
household 
contacts
Tuberculosis 
infection
Tuberculosis 
progression 
model
Case 
detection 
ratio by age
Tuberculosis 
incidence 
estimates 
0 to <5 and 
5 to <15 (WHO)
BCG coverage 
(WHO/UNICEF)
Screening and 
preventive 
therapy
Active 
case-finding 
and treatment
Child household 
contacts of 
pulmonary 
tuberculosis
Incident 
tuberculosis
Prevalent
tuberculosis
Tuberculosis 
mortality 
model
Tuberculosis 
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Life-years lostLife tables 
(WHO)
Decision tree modelDatabase
Modelling step
Intervention
Result
Figure 1: Overview of modelling logic
The dotted box shows elements of the overall model that are assessed using the decision tree model. BCG=Bacillus Calmette-Guérin vaccination.
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for 217 countries and territories.12 Missing data were 
assigned WHO regional averages. Household tuber-
culosis status was not a major additional inluence on 
numbers of cohabiting children (appendix).
Decision tree model for child contacts
A decision tree model was developed, which was based 
on published models of tuberculosis incidence13,14 and 
mortality2 in children, depending on age, HIV and 
antiretroviral therapy (ART) status, BCG vaccination 
status, and whether anti-tuberculosis treatment was 
received (igure 2). These models were extended using 
systematic review data on tuberculosis disease and latent 
tuberculosis infection co-prevalence in household 
tuberculosis contacts by age group and country income,5 
the eicacy of preventive therapy in preventing 
tuberculosis disease in children,15,16 and life expectancy by 
age and country (appendix). We assumed no further 
transmission occurred after HCM.
Data on progression risks were mainly from children 
judged to have latent tuberculosis infection by TST;17 the 
predicted number latently infected (co-prevalent active 
tuberculosis excluded) was therefore combined with 
progression rates to establish incidence. Consistent with 
these data, preventive therapy was assumed efective only 
in TST-positive children, with an eicacy based on the 
variance-weighted average of preventive therapy studies 
in only TST-positive children identiied by systematic 
review,15 and a separate eicacy for children living with 
HIV.16
The probability of children being diagnosed with 
tuberculosis disease and receiving anti-tuberculosis 
treatment in the absence of HCM was based on the case 
detection rate for each age group and country from WHO 
estimates and notiication data.12 Because children with 
tuberculosis cohabiting with  patients who have been 
diagnosed with tuberculosis are probably more likely to 
receive anti-tuberculosis treatment than average 
population-matched children with tuber culosis, we used a 
distribution that interpolated between the population 
average and an upper-bound case detection rate by an 
uncertain amount (appendix). We modelled the higher 
HIV prevalence in children living with patients with 
tuberculosis who are HIV positive using data on HIV 
prevalence by age in child household contacts of people 
with tuberculosis who are HIV positive from Uganda,18 
and the WHO data on the prevalence of HIV and ART 
among  patients diagnosed with tuberculosis.12 We 
assumed the same ART coverage in child household 
contacts as in HIV-positive  patients with diagnosed 
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Figure 2: Decision tree model for tuberculosis household contacts
ART=antiretroviral therapy. LTBI=latent tuberculosis infection. IGRA=interferon gamma release assay. TST=tuberculin skin test.
See Online for appendix
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tuberculosis (appendix). All analyses were done using the 
R environment for statistical computing, version 3.4.4.
Role of the funding source
The funders of the study had no role in the study design, 
data collection, data analysis, data interpretation, or 
writing of the report. The corresponding author had full 
access to all the data in the study and had inal 
responsibility for the decision to submit for publication.
Results
If HCM was conducted on all  patients diagnosed with 
pulmonary tuberculosis in 2016, the number of 
households visited globally would have been 5 100 000. 
This number would have reached an estimated 8 258 000 
(75% uncertainty interval [UI] 8 154 000–8 349 000) 
children younger than 15 years for screening, consisting 
of 2 789 000 (75% UI 2 744 000–2 834 000) children 
younger than 5 years and 5 469 000 (75% UI 
5 371 000–5 555 000) children aged 5–14 years (table 1). 
Without HCM (scenario A), we estimated that the 
children (all those younger than 15 years) would receive 
594 200 (75% UI 530 000–649 000) anti-tuberculosis 
treatment courses, which would increase in scenario B 
to 862 500 (75% UI 797 600–917 900) and in scenario C 
to 797 200 (75% UI 734 500–851 100), because some 
cases in scenario C would be averted by expanded 
preventive therapy use. Anti-tuberculosis treatment 
courses resulting from passive detection of incident 
and co-prevalent cases and anti-tuberculosis treatment 
courses resulting from HCM identiication and 
treatment of co-prevalent child patients are included. 
We estimated that 2 543 000 (75% UI 2 497 000–2 588 000) 
preventive therapy courses would be needed for 
scenario B and 5 174 000 (75% UI 5 076 000–5 261 000) 
courses for scenario C.
In scenario A, we estimated 996 500 (75% UI 
930 300–1 049 000) co-prevalent and incident tuberculosis 
cases in children younger than 15 years living with 
patients with diagnosed tuberculosis, resulting in 
133 500 (75% UI 123 400–142 400) deaths (table 2). We 
estimated that the majority of these tuberculosis cases 
would be in children aged 5–14 years (613 700 [75% 
UI 553 000–666 900), whereas the majority of deaths 
would be in children younger than 5 years (101 000 
[92 500–108 200]). Scenario B averted 66 700 (75% UI 
59 790–72 370) cases of tuberculosis disease, and 
scenario C averted 159 500 (75% UI 147 000–170 900) 
cases. Scenario B averted 103 600 (75% UI 94 480–111 900) 
deaths, and scenario C averted 108 400 (75% UI 
98 800–116 700) deaths; in both scenarios B and C, most 
of these averted deaths were in children younger than 
5 years. Scenario B gained 7 006 000 (75% UI 
6 373 000–7 567 000) life-years, and scenario C gained 
Scenario A: no 
household contact 
management
Scenario B: 
preventive therapy to 
children younger 
than 5 years and 
children who are HIV 
positive
Scenario C: preventive 
therapy to children 
younger than 5 years 
and children who are 
HIV positive or TST 
positive
Difference between 
B and A
Difference between 
C and A
All children younger than 15 years
Children screened 0 8 258 000 
(8 154 000–8 349 000)
·· 8 258 000 
(8 154 000–8 349 000)
··
Anti-tuberculosis treatments 594 200 
(530 000–649 000)
862 500 
(797 600–917 900)
797 200 
(734 500–851 100)
268 300 
(235 100–297 300)
202 900 
(166 000–236 400)
Preventive therapy courses 0 2 543 000 
(2 497 000–2 588 000)
5 174 000 
(5 076 000–5 261 000)
2 543 000 
(2 497 000–2 588 000)
5 174 000 
(5 076 000–5 261 000)
Children younger than 5 years
Children screened 0 2 789 000 
(2 744 000–2 834 000)
·· 2 789 000 
(2 744 000–2 834 000)
··
Anti-tuberculosis treatments 163 200 
(151 200–175 300)
295 400 
(272 500–315 300)
·· 132 200 
(115 000–147 800)
··
Preventive therapy courses 0 2 511 000 
(2 465 000–2 556 000)
·· 2 511 000 
(2 465 000–2 556 000)
··
Children aged 5–14 years
Children screened 0 5 469 000 
(5 371 000–5 555 000)
·· 5 469 000 
(5 371 000–5 555 000)
··
Anti-tuberculosis treatments 431 100 
(367 900–480 300)
567 100 
(506 400–616 900)
501 800 
(442 500–552 200)
136 000 
(107 700–158 700)
70 690 
(38 620–95 280)
Preventive therapy courses 0 31 900 
(31 100–32 690)
2 663 000 
(2 585 000–2 745 000)
31 900 
(31 100–32 690)
2 663 000 
(2 585 000–2 745 000)
Data are numbers of children (75% uncertainty interval). Anti-tuberculosis treatments include those resulting from routine services. TST=tuberculin skin test. ··indicates cells 
for which the number is the same for scenarios B and C—ie, where no additional children were eligible for preventive therapy in scenario C than scenario B. 
Table 1: Demands on the health-care system for tuberculosis household contact management interventions in children younger than 15 years
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7 305 000 (75% UI 6 663 000–7 874 000) life-years; in both 
scenarios, the most life-years were gained in children 
younger than 5 years.
The WHO southeast Asia region had the largest share 
of preventable deaths, followed by the African region, the 
western Paciic region, the eastern Mediterranean region, 
and the region of the Americas and European region 
(appendix).
Globally, only 3% of tuberculosis deaths in children 
cohabiting with patients with diagnosed tuberculosis 
with no HCM were estimated to be HIV positive, but 7% 
were estimated in the WHO African region. In scenario 
A, more than 70% of tuberculosis cases in children were 
co-prevalent upon index case notiication, rather than 
incident during the subsequent year, with a similar split 
in anti-tuberculosis treatment courses given to co-
prevalent versus incident child tuberculosis cases 
(appendix). The increases in anti-tuberculosis treatment 
courses for co-prevalent cases found by HCM (scenarios B 
and C) were partially ofset by anti-tuberculosis treatment 
courses averted through preventive-therapy-mediated 
reductions in incidence (appendix).
In scenario B versus scenario A, globally, for every 
child tuberculosis case averted, 78 (75% UI 70–85) 
households were visited, 126 (75% UI 113–138) children 
were screened, 42 (75% UI 35–39) preventive therapy 
courses were given, and an additional 4 (75% UI 3–5) 
anti-tuberculosis treatment courses were given (igure 3). 
In scenario C versus scenario A, globally, for every child 
tuberculosis case averted, 32 (75% UI 30–35) households 
were visited, 52 (75% UI 48–56) children were screened, 
33 (75% UI 30–35) preventive therapy courses were 
given, and 1 (75% UI 1–2) additional anti-tuberculosis 
treatment course was given.
In scenario B versus scenario A, globally, for every 
child tuberculosis death averted, 49 (75% UI 46–54) 
households were visited, 81 (75% UI 74–87) children were 
screened, 25 (75% UI 23–27) preventive therapy courses 
were given, and an additional 3 (75% UI 2–3) anti-
tuberculosis treatment courses were given (igure 3). In 
scenario C versus scenario A, globally, for every child 
tuberculosis death averted, 48 (75% UI 44–52) households 
were visited, 77 (75% UI 71–83) children were screened, 
48 (75% UI 44–52) preventive therapy courses were given, 
and an additional 2 (75% UI 2–2) anti-tuberculosis 
treatment courses were given (igure 3).
Discussion
In this mathematical modelling study, we found that 
HCM implemented at full scale might prevent about 
110 000 deaths and about 160 000 cases of tuberculosis 
disease in children every year. The deaths averted would 
amount to more than 7 million expected life-years saved. 
Children younger than 5 years would derive the greatest 
beneit, comprising two in every ive averted cases and 
three in every four of the averted deaths. Extending use 
of preventive therapy to TST-positive children older than 
5 years, consistent with 2018 updated WHO guidelines,7 
Scenario A: no household 
contact management
Scenario B: preventive therapy 
to children younger than 
5 years and children who are 
HIV positive
Scenario C: preventive therapy 
to children younger than 
5 years and children who are 
HIV positive or TST positive
Difference between B 
and A
Difference between C 
and A
All children younger than 15 years
Tuberculosis cases 996 500 
(930 300 to 1 049 000)
929 800 
(863 900 to 983 300)
837 000 
(771 700 to 892 400)
–66 700 
(–72 370 to –59 790)
–159 500 
(–170 900 to –147 000)
Tuberculosis deaths 133 500 
(123 400 to 142 400)
29 840 
(27 300 to 31 750)
25 130 
(22 850 to 26 880)
–103 600 
(–111 900 to –94 480)
–108 400 
(–116 700 to –98 800)
Total life expectancy (years) 526 200 000 
(519 400 000 to 532 200 000)
533 200 000 
(526 400 000 to 539 300 000)
533 500 000 
(526 700 000 to 539 600 000)
7 006 000 
(6 373 000 to 7 567 000)
7 305 000 
(6 663 000 to 7 874 000)
Children younger than 5 years
Tuberculosis cases 382 800 
(358 100 to 404 300)
318 000 
(294 500 to 338 800)
·· –64 800 
(–70 490 to –57 820)
··
Tuberculosis deaths 101 000 
(92 500 to 108 200)
17 550 
(15 520 to 19 000)
·· –83 460 
(–90 150 to –75 800)
··
Total life expectancy (years) 182 900 000 
(179 800 000 to 185 900 000)
188 600 000 
(185 400 000 to 191 700 000)
·· 5 724 000 
(5 181 000 to 6 188 000)
··
Children aged 5–14 years
Tuberculosis cases 613 700 
(553 000 to 666 900)
611 800 
(551 100 to 664 900)
519 000 
(459 300 to 569 700)
–1906 
(–2037 to –1765)
–94 710 
(–103 700 to –84 700)
Tuberculosis deaths 32 480 
(27 460 to 36 430)
12 290 
(10 810 to 13 440)
7584 
(6611 to 8334)
–20 180 
(–23 180 to –16 090)
–24 900 
(–28 450 to –20 320)
Total life expectancy (years) 343 400 000 
(337 000 000 to 348 800 000)
344 700 000 
(338 300 000 to 350 300 000)
344 900 000 
(338 600 000 to 350 600 000)
1 282 000 
(1 016 000 to 1 479 000)
1 581 000 
(1 281 000 to 1 816 000)
Data are number (75% uncertainty interval). Tuberculosis cases, deaths, and life expectancy all include contributions from incident and co-prevalent cases of tuberculosis. ·· indicates cells for which the number is 
the same for scenarios B and C because no additional children were eligible for preventive therapy in scenario C than scenario B. TST=tuberculin skin test.
Table 2: Morbidity and mortality outcomes for tuberculosis household contact management interventions in children younger than 15 years
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would more than double the number of paediatric 
cases averted.
We have considered the scenario in which long-
time recommended interventions are implemented for 
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Figure 3: Impact of fully implemented household contact management in children younger than 15 years as incremental demands on the health-care system 
required to avert one tuberculosis case or death
(A) Scenario B versus scenario A. (B) Scenario C versus scenario A. Error bars show 75% uncertainty interval. Scenario A=no household contact management. Scenario 
B=preventive therapy to children younger than 5 years and children who are HIV positive. Scenario C=preventive therapy to children younger than 5 years and children 
who are HIV positive or TST positive.
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children exposed at home to tuberculosis, with perfect 
coverage of both screening and treatments. We have not 
considered the best approaches for achieving these ends, 
and varying approaches would probably be needed in 
diferent contexts. We have also not considered the true 
economic costs of these activities, nor considered the 
quality-of-life gains from reductions in tuberculosis 
disease and its sequelae. Our aim was to project the 
expected beneits, in terms of the reduction of 
tuberculosis disease and death in children, that could be 
achieved through child-speciic household management 
interventions. Certainly, the numbers of children 
screened and given preventive therapy estimated by this 
model are large, and the numbers of children screened 
and treated are far greater than those that most 
tuberculosis programmes achieve, but some examples of 
successful implementations in resource-limited settings 
do exist.19 Quantifying this additional workload is a irst 
step for global planning: projecting the action required—
ie, the numbers of household visits, children screened, 
and preventive therapy courses needed. The numbers of 
children screened that was required to avert one 
tuberculosis death compare favourably with estimates of 
numbers needed to screen to ind one case for other 
tuberculosis screening activities.20
These results can be used to help identify the envelope 
within which alternative service provisions might be 
deemed cost-efective in diferent countries. Evidence 
shows that interventions generating health gain at less 
than US$200 per disability-adjusted life-year (DALY) 
averted would be deemed cost-efective in many 
countries,21 even those classiied as amongst the poorest 
in the world. Assuming that each death avoided generates 
30 DALYs averted per child saved after discounting, a 
country programme able to pay $200 per DALY averted 
should be willing to spend up to $6000 ($200 times 30) 
to save one child’s life. The question is whether the costs 
required to do this (here estimated for scenario B as 
making 50 household visits, screening 80 children for 
active tuberculosis, administering 25 preventive therapy 
courses, and giving three courses of anti-tuberculosis 
treatment) plus any net downstream costs of treatments 
can be delivered within this budget. Analyses of the 
health system costs of contact screening and diagnosing 
and treating tuberculosis infection from Uganda, 
Malaysia, and Vietnam suggest that this is a highly 
feasible target.22–24 If in a particular setting the costs of 
intervention exceed this amount, then a priority task 
becomes how to deliver the necessary interventions more 
eiciently.
To reliably establish the cost-efectiveness of scaling up 
household contact management across diferent 
countries, full costing of those interventions would be 
required, as well as establishing measures of morbidity 
and mortality such as DALYs. One would need to consider 
the feasibility of delivery given constraints within health-
care systems and uptake by diferent population groups. 
All these factors are context speciic and could depend 
importantly upon the scale of delivery (eg, average costs 
might fall initially as intervention programmes are scaled 
up, but rise as they are taken into hard-to-reach areas). 
This scaling up of delivery should be the focus for further 
research, in which epidemiological and health economic 
modellers work hand-in-hand with implementation 
scientists. Novel models of service provision might have 
advantages, such as the use of community health workers 
or integration with maternal and child health pro-
grammes; these will need to be assessed using 
implementation research. Mandatory monitoring and 
reporting are often necessary to drive implementations 
of this kind. The health technology landscape is also 
changing rapidly. Shorter, more patient-acceptable and 
more implement able treatments for tuberculosis 
infection would help to increase uptake of preventive 
therapy and promote adherence to treatment 
completion.25 Additionally, the development of tests that 
could better identify those at increased risk of progressing 
to tuberculosis disease would mean that fewer contacts 
would require preventive therapy.26
We have considered full coverage of the intervention 
scenarios, but we used yield data from household 
screening activities that used imperfectly sensitive and 
speciic approaches to diagnosing tuberculosis disease 
in child household contacts, after realistic delays in 
reaching households (during which tuberculosis could 
have developed or deaths occurred). These imperfect 
approaches are also the basis of entry to the studies on 
which we base our estimates of risk of death with treated 
and untreated tuberculosis disease. We have modelled 
TST-positivity rather than true latent tuberculosis 
infection because this is what most of the data on 
household infection rates and progression rates are 
based on. We might therefore have been conservative in 
our assessment of preventive therapy efect, in assuming 
no beneit to TST-negative children.
Our analysis is also subject to several simpliications. 
Our scope explicitly excluded beneits and treatments in 
cohabiting adults, who would normally be screened for 
tuberculosis disease. The treatment of these adults is 
anticipated to increase efects with limited increases in 
demand on the health-care system. We also limited HCM 
to patients with pulmonary tuberculosis; HCM for other 
forms of tuberculosis might provide beneits by 
identifying children at risk from a common exposure. 
We assumed that the number of cohabiting children 
depended on adult age and sex but was not diferent for 
households of patients with diagnosed tuberculosis. An 
analysis for India (appendix) suggested this assumption 
to be reasonable. We also made the simplifying 
assumptions that all diagnosed patients with tuberculosis 
lived in households and that none shared a household, 
which could potentially have overestimated the number 
of children living in households afected by tuberculosis. 
However, the pro portion of diagnosed adults sharing a 
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house is small,5 and by only considering children 
cohabiting with patients with tuberculosis, we 
conservatively underestimate the reach of contact 
manage ment, which should include non-cohabiting 
young children who have spent signiicant time in the 
household. This time spent might include contact with 
caregivers, such as grandparents, who do not live with 
the child. We were similarly conservative in assuming 
that household management would not improve house-
hold awareness of tuberculosis and therefore improve 
case detection in subsequent incident disease in children. 
We also did not make allowance for any reductions in life 
expectancy in children living with HIV (although 
children with HIV contributed a small fraction of deaths). 
Furthermore, we did not consider multidrug-resistant 
tuberculosis, which is expected to afect about 3% of 
children with tuberculosis;27 children with multidrug-
resistant tuberculosis comprise a group with diferent 
case detection rates and treatment and preventive therapy 
outcomes. Given how few children with drug-resistant 
tuberculosis are diagnosed and treated, the efect of 
appropriate household management might be even more 
pronounced than for patients with drug-susceptible 
tuberculosis. A study published in 2018 estimated that 
with universal HCM after the diagnosis of an adult with 
multidrug-resistant tuberculosis, 12 times as many 
children would be treated for multidrug-resistant 
tuberculosis than are currently.27
Our analysis is the irst to project the total global health 
impact that could be achieved by child-targeted household 
management. We emphasise uncertainty propagation, 
and a detailed model of tuberculosis natural history in 
children. Our study brings together estimates of 
household structure and a model of intervention efect 
and outcomes focused on children, and it uses evidence 
from systematic reviews from the past 5 years.3,5,15,16 Yuen 
and colleagues28 estimated numbers of children with 
co-prevalent disease in household contacts, obtaining 
similar results to ours. A cost-efectiveness modelling 
study29 considered tuberculosis infection testing and 
preventive therapy to reduce tuberculosis incidence in 
cohorts of child household contacts younger than 5 years 
for a particular setting, concluding that all strategies 
were cost-efective. We included both these elements—
the substantial beneits from household management to 
co-prevalent paediatric cases and the reductions in 
incidence from preventive therapy—and extended our 
analysis to 217 countries and territories. The balance 
between cases averted through preventive therapy and 
deaths averted depends strongly on the co-prevalence 
levels from a systematic review;5 lower co-prevalence in 
some settings would shift the beneits of HCM towards 
those derived from case prevention rather than case 
inding. However, our lower projected demands on the 
health-care system per death averted than per case 
averted indicates that HCM achieves substantial beneit 
through its case-inding component and cannot simply 
be considered as a mode of delivering preventive therapy. 
Benchmarking our estimates of cases averted against 
global incidence estimates of about 1 million tuberculosis 
cases in children per year suggests that 16% of incidence 
could be avoided by full HCM implementation. Although 
a direct comparison is not appropriate between the global 
mortality estimates of 250 000 child tuberculosis deaths 
per year and our estimate of 110 000 deaths averted after 
1 year of full HCM because the case-inding intervention 
component includes prevalent cases incident in previous 
years, this inding does indicate the potential for a large 
impact on mortality.
HCM for tuberculosis has the potential to prevent 
substantial morbidity and mortality in children, with 
impact-for-efort that compares favourably with other 
interventions. The low global coverage of this efective 
intervention needs to increase; funding and implemen-
tation research to enable this should be prioritised.
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